Edwards Lifesciences Corp (NYSE:EW)

CAPS Rating: 4 out of 5

A global provider of products and technologies designed to treat advanced cardiovascular disease. The Company focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical care technologies.

Results 1 - 20 of 21 : 1 2 Next »

Recs

0
Member Avatar dreamjob (87.19) Submitted: 5/1/2015 10:52:01 AM : Outperform Start Price: $128.66 EW Score: +11.79

High Quality, and Cheap. Growing Sales, Earnings, and Book Value. Strong ROIC. Priced below Intrinsic Value. Quality Earnings.

Recs

0
Member Avatar byzantium100 (< 20) Submitted: 4/30/2015 9:44:21 PM : Outperform Start Price: $127.12 EW Score: +13.06

Sales, Earnings, and Book Value are growing at double digit rates. ROIC is strong, and growing. Generating an abundance of free cash flow. Priced well below intrinsic value. I think a more fair price would be closer to $200 / share.

Recs

0
Member Avatar AnxiousBorrower (88.02) Submitted: 4/17/2015 1:18:16 AM : Outperform Start Price: $140.78 EW Score: +1.97

Unique Medical device in an environment where acquisitions are expected.

Recs

0
Member Avatar KimPutin (47.70) Submitted: 3/28/2015 9:27:29 PM : Outperform Start Price: $144.87 EW Score: -1.83

Watch out for John Hancock on the Declaration of Independence if you ever visit D.C. without an iPhone.

Recs

0
Member Avatar tiomiguel (76.13) Submitted: 2/24/2015 7:22:54 PM : Outperform Start Price: $133.66 EW Score: +8.63

Using the "PE Relative Valuation" calculation, this stock is actually under-priced by about 47%. Other ratios that indicate this is still a good value are "PE to 5-year-average PE" (0.62), PEG (using trailing 5-year EPS growth + dividends) of 0.6. Still more good numbers: TTM ROE of 43.3; LT Debt/Equity of 27.3; current ratio of 5.3; consistent EPS growth over 1-,3-, 5-, and 7-year periods; operating and net margins way over the Medical Equipment & Supples industry average. I hope all this justifies jumping near its all-time high!

Recs

0
Member Avatar moneymn (80.11) Submitted: 1/7/2015 6:38:27 PM : Outperform Start Price: $131.02 EW Score: +7.11

Saipen. Best heart valves

Recs

0
Member Avatar LoveMeSomeGreen (98.95) Submitted: 11/22/2013 10:26:19 AM : Outperform Start Price: $64.53 EW Score: +105.66

Contrarian buy - charts haven't looked good, but I think it could be in for a reversal.

Was recently featured in a great article on seeking alpha detailing stocks that have outperformed the market w/ a low beta.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/26/2013 7:50:39 PM : Outperform Start Price: $72.40 EW Score: +70.62

Long. Medical device company is growing nicely, has a good balance sheet and trading at a fair valuation.

Recs

0
Member Avatar ROEoutshinesGOLD (99.54) Submitted: 7/12/2013 11:50:09 AM : Outperform Start Price: $67.23 EW Score: +81.36

EW announces that the District Court of Mannheim, Germany found that MEDTRONIC infringes EWs' Spenser patent for trans-catheter heart valve technology.
Says the court granted an injunction prohibiting the sale of CoreValve and CoreValve Evolut systems in Germany, a recall of these products, and an accounting for past damages.
___________________________________________________________________________________________________

S&P 4**** STAR

This company makes and markets a comprehensive line of products and services to treat late-stage cardiovascular disease.

We view EW's TAV and surgical heart valve businesses as defensive lines that should continue to post solid results. In this regard, we were encouraged by the strong, late-2011 U.S. launch of the SAPIEN. Moreover, that launch was only for its implantation in patients unable to undergo open-heart surgery via the trans-femoral approach. We believe the potential patient population expanded with the FDA's later approvals for TA implantation and implantation in high-risk patients. Looking ahead, we believe the TA training delay by some centers is temporary and the consignment conversion will mask the procedure count. We expect the procedure count will continue to rise at a still-healthy clip over the long term. We also view potential Japanese approval for the next-generation SAPIEN XT as a catalyst.

We forecast revenue growth of 8.5% in 2013.
We see this growth mainly driven by a 27%-28% increase in trans-catheter aortic valve (TAV) revenues, amid a still-strong demand for TAV implantation in the U.S. However, while U.S. TAV sales should benefit from the new hospital implantation centers and hospitals stocking the new SAPIENs for trans-apical (TA) implantation, 20 centers delayed TA training. EW also notes that some centers were realizing capacity constraints and certain others are questioning profitability based on regional Medicare reimbursement. In addition, reported sales will likely be pressured in the second half, on the conversion of hospitals that initially placed stocking orders and implanted 20-30 TAVs to consignment accounts. Meanwhile, we look for 2%-3% growth in constant currency for surgical heart valve and critical care product sales.

We expect gross margins to widen in 2013, mainly on an improving product mix, while the operating cost ratio declines, despite the 2013 onset of the U.S. medical device tax.

We see adjusted EPS of $3.10 in 2013, versus $2.69 in 2012, and we look for $3.63 in 2014.

Our 12-month target price of $80 reflects a multiple of 29X our 2013 EPS estimate, below the stock's recent averages due to near-term headwinds we see.

Risks to our recommendation and target price include market share losses in key product categories and inability to successfully commercialize products in the pipeline.

Recs

0
Member Avatar gotchey (< 20) Submitted: 5/18/2013 12:27:47 AM : Outperform Start Price: $67.00 EW Score: +88.31

Was hit to hard for earnings and getting a new CEO.

Recs

0
Member Avatar NHWeston (20.90) Submitted: 9/7/2012 10:40:51 AM : Outperform Start Price: $107.23 EW Score: -10.96

As the "bionic-being" lifestyle becomes more achieveable, EW will lead the way in "auto-heart" technology.

Recs

0
Member Avatar schmidty412 (< 20) Submitted: 7/28/2012 5:58:15 AM : Outperform Start Price: $105.22 EW Score: -14.28

The Saphien heart valve is a monster piece of technology. It gives a surgery option to a large set of older people who couldn't have open heart. There isnt a competitor in this space, and hospitals worldwide are having to look to cut costs. Saphien is much less invasive, which means faster recovery. It was a technology developed in-house as is most of their products.

Recs

0
Member Avatar gorjo (< 20) Submitted: 5/10/2011 3:11:08 AM : Outperform Start Price: $88.20 EW Score: +8.14

Innovative new technology. Industry leader.

Recs

0
Member Avatar lacostakid (80.30) Submitted: 12/31/2010 2:07:08 PM : Outperform Start Price: $81.53 EW Score: +11.11

good sales and earnings growth

Recs

0
Member Avatar blocksofstock (< 20) Submitted: 10/18/2010 2:29:57 PM : Outperform Start Price: $67.00 EW Score: +37.33

Pipeline pdts. + candidate to be bought

Recs

0
Member Avatar WilliamCrook2007 (< 20) Submitted: 11/20/2008 2:47:03 PM : Outperform Start Price: $23.23 EW Score: +343.95

ibd

Recs

0
Member Avatar robo2011 (49.75) Submitted: 7/20/2008 11:32:25 PM : Underperform Start Price: $33.13 EW Score: -260.86

Overvalued and at the top of a 52 week high, this stock is ripe and ready for a fall.

Recs

0
Member Avatar jetlith (39.27) Submitted: 7/3/2008 4:06:35 PM : Underperform Start Price: $30.79 EW Score: -293.97

gone up wayyyyyy too high, especially in this bear market.. and YoY eps has been dropping big. I expect a correction back down to the 40's.

Recs

0
Member Avatar ScreenerStizBear (67.64) Submitted: 6/26/2008 2:29:59 PM : Underperform Start Price: $31.15 EW Score: -291.42

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Recs

0
Member Avatar joelima (< 20) Submitted: 4/11/2008 4:08:21 PM : Outperform Start Price: $23.12 EW Score: +453.97

Great pipeline

Results 1 - 20 of 21 : 1 2 Next »

Featured Broker Partners


Advertisement